C-reactive protein and statins: IL-8 as a molecular link?

Clinical Science

Volumn 108, Issue 6, 2005, Pages 493-495

  Szmitko, Paul E ^a   Verma, Subodh ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

3 hydroxy 3 methylglutaryl CoA (HMG CoA) reductase inhibitor; Atherosclerosis; C reactive protein (CRP); Interleukin 8; Mitogen activated protein kinase (MAPK); Statin

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PITAVASTATIN; ROSUVASTATIN;

ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR ENDOTHELIUM;

AORTA; C-REACTIVE PROTEIN; CELLS, CULTURED; DEPRESSION, CHEMICAL; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-8; P38 MITOGEN-ACTIVATED PROTEIN KINASES; QUINOLINES;

EID: 20444471114     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050093     Document Type: Review

References (21)

1. Szmitko, P. E., Wang, C. H., Weisel, R. D. et al. (2003) New markers of inflammation and endothelial cell activation: part I. Circulation 108, 1917-1923
2. Verma, S., Szmitko, P. E. and Ridker, P. M. (2005) C-reactive protein comes of age. Nat. Clin. Practice Cardiovasc. Med. 2, 29-36
3. Pearson, T. A., Mensah, G. A., Alexander, R. W. et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511
4. Kibayashi, E., Urakaze, M., Kobashi, C. et al. (2005) Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells. Clin. Sci. 108, 515-521
5. Verma, S., Badiwala, M. V., Weisel, R. D. et al. (2003) C-reactive protein upregulates the NFκB signalling pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J. Thorac. Cardiovasc. Surg. 126, 1886-1891
6. Verma, S., Li, S. H., Kuliszewski, M. A. et al. (2004) C-reactive protein attenuates endothelial progenitor cell survival, differentiation and function: further evidence of a mechanistic link between CRP and cardiovascular disease. Circulation 109, 2058-2067
7. Szmitko, P. E., Fedak, P. W. M., Weisel, R. D. et al. (2003) Endothelial progenitor cells: new hope for a broken heart. Circulation 107, 3093-3100
8. Wang, C. H., Li, S. H., Weisel, R. D. et al. (2003) C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107, 1783-1790
9. Williams, T. N., Zhang, C. X., Game, B. A., He, L. and Huang, Y. (2004) C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fcγ RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler., Thromb., Vasc. Biol. 24, 61-66
10. Devaraj, S., Xu, D. Y. and Jialal, I. (2003) C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404
11. Khreiss, T., Jozef, L., Potempa, L. A. et al. (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109, 2016-2022
12. Danenberg, H. D., Szalai, A. J., Swaminathan, R. V. et al. (2003) Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108, 512-515
13. Paul, A., Ko, K., Li, L. et al. (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109, 647-655
14. a Erratum (2004) Circulation 109, 2254
15. Li, S. H., Szmitko, P. E., Weisel, R. D. et al. (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 109, 833-836
16. Devaraj, S., Kumaresan, P. R. and Jialal, I. (2004) Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J. Mol. Cell. Cardiol. 36, 405-410
17. Qamirani, E., Ren, Y., Kuo, L. and Hein, T. W. (2005) C-reactive protein inhibits endothelium-dependent NO-mediated dilatation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler., Thromb., Vasc. Biol., doi:10.1161/01.ATV.0000159890.10526.1e
18. Seeger, F. H., Haendeler, J., Walter, D. H. et al. (2005) p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 111, 1184-1191
19. Ridker, P. M., Cannon, C. P., Morrow, D. et al. (2005) C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28
20. Nissen, S. E., Tuzcu, E. M., Schoenhagen, P. et al. (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38
21. Ridker, P. M. on behalf of the JUPITER study group (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108, 2292-2297